###begin article-title 0
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fn" rid="FN1">*</xref>
###xml 79 79 79 79 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="sbox.jpg"/>
###xml 79 79 79 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><inline-graphic xlink:href="sbox.jpg"/></sup>
###xml 79 79 79 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fn" rid="FN2"><sup><inline-graphic xlink:href="sbox.jpg"/></sup></xref>
A Mediator of Rho-dependent Invasion Moonlights as a Methionine Salvage Enzyme*
###end article-title 0
###begin p 1
dagger Deceased January 8, 2009.
###end p 1
###begin p 2
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>b</sup></italic>
b Present address: Division of Applied Biochemistry, Dept. of Bioproductive Science, Utsunomiya University, Tochigi 321-8505, Japan.
###end p 2
###begin p 3
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>d</sup></italic>
d Present address: OSI Pharmaceuticals Inc., 1 Bioscience Park Dr., Farmingdale, NY 11735.
###end p 3
###begin p 4
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</sup>
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>f</sup></italic>
f Present address: Orion Pharma, Orionintiel, P.O. Box 65, FI-02101 Espoo, Finland.
###end p 4
###begin p 5
###xml 1049 1050 1049 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 1215 1216 1215 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 346 351 <span type="species:ncbi:9606">human</span>
###xml 512 517 <span type="species:ncbi:9606">human</span>
RhoA controls changes in cell morphology and invasion associated with cancer phenotypes. Cell lines derived from melanoma tumors at varying stages revealed that RhoA is selectively activated in cells of metastatic origin. We describe a functional proteomics strategy to identify proteins regulated by RhoA and report a previously uncharacterized human protein, named "mediator of RhoA-dependent invasion (MRDI)," that is induced in metastatic cells by constitutive RhoA activation and promotes cell invasion. In human melanomas, MRDI localization correlated with stage, showing nuclear localization in nevi and early stage tumors and cytoplasmic localization with plasma membrane accentuation in late stage tumors. Consistent with its role in promoting cell invasion, MRDI localized to cell protrusions and leading edge membranes in cultured cells and was required for cell motility, tyrosine phosphorylation of focal adhesion kinase, and modulation of actin stress fibers. Unexpectedly MRDI had enzymatic function as an isomerase that converts the S-adenosylmethionine catabolite 5-methylribose 1-phosphate into 5-methylribulose 1-phosphate. The enzymatic function of MRDI was required for methionine salvage from S-adenosylmethionine but distinct from its function in cell invasion. Thus, mechanisms used by signal transduction pathways to control cell movement have evolved from proteins with ancient function in amino acid metabolism.
###end p 5
###begin p 6
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
Cutaneous malignant melanoma has doubled in incidence over the past 30 years. Stages involved in progression of melanocytes to melanoma based on clinical and histopathological features include nontumorigenic nevi, dysplastic or atypical nevi, primary radial growth phase and vertical growth phase melanoma, and metastatic melanoma (1). Metastatic melanomas are often resistant to treatment; therefore therapeutic strategies require a more complete understanding of molecular determinants of this disease, particularly those involved in the invasive phenotype (2).
###end p 6
###begin p 7
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 213 221 213 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 619 620 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 620 620 620 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7"/>
###xml 621 622 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 937 938 937 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1204 1206 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1208 1210 1208 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 401 406 <span type="species:ncbi:10090">mouse</span>
###xml 421 426 <span type="species:ncbi:9606">human</span>
###xml 489 494 <span type="species:ncbi:9606">human</span>
Rho GTPases control a wide range of cellular responses including cell movement, morphogenesis, and coordinated migration (3). These pathways are implicated in malignant cell transformation and metastasis based on in vitro evidence showing tumorigenic and invasive responses to enhanced signaling in cell lines. Studies have demonstrated that overexpression of RhoC enhances invasion and metastasis in mouse xenografts of human melanoma and lung cancer cell lines (4, 5). In addition, some human tumors show elevated expression of Rho GTPases and exchange factors and/or reduced expression of GTPase-activating factors (6-8). Signaling through RhoA promotes actin polymerization and stress fiber formation, providing cells with contractile force needed for cell movement. Rho-GTP interacts with various effectors, including Rho-activated kinase, which promotes actin-myosin assembly via phosphorylation of myosin light chain phosphatase (9), or diaphanous-related formins, which nucleate actin filaments and stabilize microtubules (10, 11). Studies of cultured melanoma cells have revealed an "amoeboid" invasion mechanism involving RhoA-dependent Rho-activated kinase activation and inactivation of Rac (12, 13).
###end p 7
###begin p 8
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 235 236 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fn" rid="G1"><sup>1</sup></xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 360 363 360 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
RhoA also controls the formation and turnover of focal adhesion contacts, which mediate interactions between extracellular matrix and the actin cytoskeleton (14, 15). Signaling involves activation of Src and focal adhesion kinase (FAK)1 and subsequent tyrosine phosphorylation of proteins recruited to integrin receptor complexes (16). Embryonic cells from FAK-/- mice lose motility and cannot be rescued with FAK harboring a Y397F autophosphorylation site mutation not because they fail to form focal adhesions but because they are unable to disassemble focal adhesions (17). Thus, Rho controls cell movement by modulating the turnover of focal adhesion complexes via FAK. However, the mechanisms by which Rho GTPases control FAK are incompletely understood.
###end p 8
###begin p 9
###xml 292 297 <span type="species:ncbi:9606">human</span>
###xml 587 592 <span type="species:ncbi:9606">human</span>
###xml 788 793 <span type="species:ncbi:4932">yeast</span>
###xml 922 927 <span type="species:ncbi:9606">human</span>
In this study, we report that RhoA was constitutively activated in melanoma cells in a stage-specific pattern with elevated activity in cells from metastatic tumors. We present a functional proteomics screen for molecular targets of RhoA from which we identified a previously uncharacterized human protein induced in response to constitutive RhoA activation. This protein promoted Rho-dependent cell invasion and cell motility and provided a novel link for regulation of FAK tyrosine phosphorylation by RhoA. Thus, we refer to it as "mediator of Rho-dependent invasion (MRDI)." Although human MRDI has not been studied previously, it shows close sequence similarity to a methylthioribose-1-phosphate isomerase, which functions in methionine salvage pathways characterized in bacteria and yeast. We demonstrated that MRDI indeed has methylthioribose-1-phosphate isomerase activity and is required for methionine salvage in human cells. We further demonstrated that the catalytic activity of MRDI is independent of its role in cell invasion. Thus, MRDI is a dual function protein with promiscuous roles both as a metabolic enzyme and as an effector of signaling and cancer cell invasion.
###end p 9
###begin title 10
MATERIALS AND METHODS
###end title 10
###begin title 11

###end title 11
###begin title 12

###end title 12
###begin title 13
Cell Culture
###end title 13
###begin p 14
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 122 122 122 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19"/>
###xml 122 122 122 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20"/>
###xml 122 122 122 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21"/>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 756 758 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1227 1228 1219 1220 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 176 181 <span type="species:ncbi:9606">Human</span>
Melanoma cell lines were obtained from ATCC or from Meenhard Herlyn (Wistar Institute) and maintained in 10% FBS, RPMI (18-22). Representative cell morphologies are shown in . Human primary melanocyte cell lines (FOM71 and FOM78 from Dr. Herlyn; NHEM2493 and NHEM693 from BioWhittaker) were maintained in Medium 154 with melanocyte growth supplement (Cascade Biologics). At 70% confluence, cells were incubated for 24 h in 0.01% FBS, RPMI; then lysed; and extracted for two-dimensional electrophoresis (2DE). WM35 cells were also stably transfected with pMIG-RhoC (4) or control vector. Adenoviruses expressing constitutively active mutants RhoA-V14 or Rac1-V12 were prepared by recombination into the Ad5 genome using a beta-galactosidase shuttle vector (23). Adenoviruses expressing dominant negative RhoA-N19 or Rac1-N17 were a gift from Joan Heller Brown (University of California San Diego). Infection was carried out at 10-20 plaque-forming units/cell for 24-48 h in 10% FBS, RPMI yielding >95% cell expression efficiency. In some cases cells were pretreated with Y27632 (30 mug/ml; Calbiochem), actinomycin (10 mug/ml; Sigma), cycloheximide (10 mug/ml; Sigma), C3 transferase (30 mug/ml), or lysophosphatidic acid (20 mum; Sigma). Transient transfection (90% efficiency) was obtained with FuGENE:cDNA (6:2) in retinal pigment epithelial cells (hTERT-RPE, Clontech) grown in 10% FBS, Dulbecco's modified Eagle's medium, F-12.
###end p 14
###begin title 15
Vectors for Protein Expression and RNA Interference
###end title 15
###begin p 16
###xml 174 190 174 190 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Escherichia coli</named-content>
###xml 195 196 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 243 244 240 241 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 276 283 273 280 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">E. coli</named-content>
###xml 418 419 415 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 466 467 463 464 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 487 488 484 485 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 497 498 494 495 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 883 885 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 174 190 <span type="species:ncbi:562">Escherichia coli</span>
###xml 276 283 <span type="species:ncbi:562">E. coli</span>
###xml 362 380 <span type="species:ncbi:12227">tobacco etch virus</span>
###xml 572 577 <span type="species:ncbi:9606">human</span>
MRDI was PCR-amplified from I.M.A.G.E. clone MGC3207 (Invitrogen) and subcloned into pCMV plasmid for expression in mammalian cells and into pMS356 plasmid for expression in Escherichia coli. His6-MRDI was purified after isopropyl 1-thio-beta-d-galactopyranoside induction in E. coli by nickel-nitrilotriacetic acid affinity chromatography and then treated with tobacco etch virus protease to remove the N-terminal His6 tag. Proteins were stored at 3-4 mg/ml in 20 mm Tris, pH 8.0, 150 mm KCl, 5 mm 2-mercaptoethanol at -80 degreesC. A plasmid for bacterial expression of human methylthioadenosine phosphorylase (pQE32) was a kind gift from Drs. Indranil Basu and Vern Schramm (Albert Einstein College of Medicine). This was used to produce recombinant methylthioadenosine (MTA) phosphorylase purified by nickel-nitrilotriacetic acid affinity chromatography as described previously (24).
###end p 16
###begin p 17
###xml 967 969 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
Double-stranded RNA interference (RNAi) oligonucleotides (200 pmol) were transfected into cells using DMRIE-C (1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide and cholesterol; Invitrogen). To inhibit RhoA or RhoC protein expression, cells were incubated for 48 h with oligonucleotide sequences (RhoA, 5'-GCAGGUAGAGUUGGCUUUGUU-3'; RhoC, 5'-GGAGAGAGCUGGCCAAGAUUU-3'), transfecting cells once at 0 h and again at 24 h. Cells were changed into medium containing 0.01% FBS, RPMI after the final transfection and then harvested at 48 h for Western blotting or applied to Matrigel assays for 24 h. To inhibit MRDI expression, cells were incubated for 48 h with four oligonucleotide sequences (1, 5'-GCAAGGAGATCATTATTGA-3'; 2, 5'-GCCAGGAGCTGACCGATGT-3'; 3, 5'-GCCCACCGCTGTCAACATG-3'; 4, 5'-GGATGGAACCCTAGATGGA-3'; Dharmacon) and then examined for phalloidin staining or Western blotting or applied to Matrigel assays for 24 h. Lamin A/C RNAi oligonucleotide (25) was used as a control.
###end p 17
###begin p 18
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 518 519 518 519 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 521 523 521 523 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AT</underline>
###xml 524 525 524 525 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 527 528 527 528 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 636 637 636 637 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</underline>
###xml 685 686 685 686 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 809 812 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Stable knockdown of MRDI was carried out in A375 cells by infection with lentivirus directing expression of green fluorescent protein and a U6 RNA promoter-driven shRNA-MRDI hairpin (FG12; Ref. 26) containing RNAi sequence 4. Stable transfectants were enriched by fluorescence-activated cell sorting using green fluorescent protein epifluorescence. MRDI-shRNA cells were then infected with retrovirus directing expression of MRDI containing five silent mutations (underlined) within the 19-bp shRNA sequence (5'-GGATGGCACATTGGACGGA-3') generated by site-directed mutagenesis. MRDI-WT and active site mutations C168S (5'-GACTGTGCTGACCCACAGTAACACTGGTGCTC-3') and D248A (5'-GGTCGTGGGAGCTGCCCGCGTGGTTGC-3') containing silent mutations (underlined) were subcloned into the retroviral vector pREX for expression of CMV-MRDI and the extracellular domain of CD2. Stable knockdown and add-back expression cells were then enriched by fluorescence-activated cell sorting using anti-CD2-phycoerythrin (BD Pharmingen). Site-directed mutagenesis was carried out using the QuikChange site-directed mutagenesis system (Stratagene).
###end p 18
###begin title 19
2DE and Mass Spectrometry
###end title 19
###begin p 20
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 329 331 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 333 335 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 735 736 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 743 744 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 894 896 892 894 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sub>
###xml 1242 1247 <span type="species:ncbi:9606">human</span>
###xml 1248 1253 <span type="species:ncbi:10090">mouse</span>
Cells were washed two times with PBS, extracted, and processed for isoelectric focusing as described previously (27) using Immobiline dry strips (pI 4-7, 18 cm; Amersham Biosciences) and 8-18% SDS-PAGE. Analytical (150 mug) or preparative (400 mug) gels were silver-stained using formaldehyde or methanol fixation, respectively (28, 29). Gels were analyzed with Melanie III (GeneBio), measuring protein intensities by percent volume (pixel intensities integrated over each area and divided by the sum of all intensities) and correcting each spot volume by subtracting a background volume of equal area. Changes were accepted when at least three gels from two independent experiments showed significant change in intensity by Student's t test (p < 0.01). Proteins were excised from wet gels, destained, digested in-gel with modified porcine trypsin (100 ng/digestion; Promega), and desalted on C18 ZipTips (Millipore). Peptides were cocrystallized with 2,5-dihydroxybenzoic acid on MALDI plates and analyzed using a Pulsar QqTOF mass spectrometer (Applied Biosystems). Peptide fingerprint spectra were summed over 50 acquisitions, and masses of the highest intensity peaks were matched against the NCBInr database (version 2005.01.06, 262,999 human/mouse entries) using MS-Fit. Searches specified trypsin cleavages with Cys-carbamidomethyl fixed and oxidized Met variable modifications allowing two missed cleavages, and peptide standards were used for external mass calibration. Details of results and excluded ions are listed in . At least two unique peptides in each digest were sequenced by MS/MS to confirm protein identifications where fragment peaks were chosen manually and searched against the NCBInr database using MS-Tag (). Mass tolerances of precursor and fragment ions were 0.1 Da. Each MS/MS spectrum was manually validated before acceptance.
###end p 20
###begin title 21
Antibodies and Western Blotting
###end title 21
###begin p 22
###xml 24 25 24 25 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 56 57 56 57 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 573 576 564 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">397</sup>
###xml 770 773 761 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">696</sup>
###xml 1283 1285 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 269 274 <span type="species:ncbi:10090">mouse</span>
###xml 313 318 <span type="species:ncbi:10090">mouse</span>
###xml 382 386 <span type="species:ncbi:9925">goat</span>
###xml 458 464 <span type="species:ncbi:9986">rabbit</span>
###xml 532 537 <span type="species:ncbi:10090">mouse</span>
###xml 596 602 <span type="species:ncbi:9986">rabbit</span>
###xml 629 634 <span type="species:ncbi:10090">mouse</span>
###xml 726 732 <span type="species:ncbi:9986">rabbit</span>
###xml 783 789 <span type="species:ncbi:9986">rabbit</span>
###xml 809 815 <span type="species:ncbi:9986">Rabbit</span>
###xml 915 920 <span type="species:ncbi:9606">human</span>
###xml 1015 1020 <span type="species:ncbi:10090">mouse</span>
###xml 1027 1033 <span type="species:ncbi:9986">rabbit</span>
###xml 1081 1085 <span type="species:ncbi:9925">goat</span>
###xml 1140 1151 <span type="species:ncbi:3704">horseradish</span>
Cells were lysed in 50 mm Tris-HCl, pH 7.2, 2% SDS, 10 mm dithiothreitol, and protein concentration was determined using the DC assay (Bio-Rad). Extracts (30 mug) were separated by SDS-PAGE and transferred to PVDF membranes. Primary antibodies recognized RhoA (1:1000, mouse; ARH01, Cytoskeleton, Inc. or 1:1000, mouse; sc-13569(16C4), Santa Cruz Biotechnology, Inc.), RhoC (1:250, goat; sc-2648(G12), Santa Cruz Biotechnology, Inc.), gamma-tubulin (1:1000, rabbit; sc-10732, Santa Cruz Biotechnology, Inc.), alpha-tubulin (1:1000, mouse; 3A2, Synaptic Systems), FAK-Tyr(P)397 (Westerns: 1:1500, rabbit; BIOSOURCE), FAK (1:1000, mouse; 610087, BD Transduction Laboratories), myosin phosphatase target subunit (MYPT1) (1:5000, rabbit; PRB-457C, Upstate), and MYPT1-Thr(P)696 (1:1000, rabbit; 07-251, Covance). Rabbit polyclonal antibodies were raised against a synthetic peptide corresponding to residues 356-369 of human MRDI (TISSRDGTLDGPQM; Sigma-Genosys) and used at 1:3000 dilution. Blots were probed with anti-mouse, anti-rabbit (Jackson ImmunoResearch Laboratories), or anti-goat (Calbiochem) secondary antibody (1:10,000) coupled to horseradish peroxidase and visualized by enhanced chemiluminescence (Amersham Biosciences). Intensities were quantified using ImageJ software (30).
###end p 22
###begin title 23
Microscopy
###end title 23
###begin p 24
###xml 515 518 515 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">397</sup>
###xml 588 591 588 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">118</sup>
###xml 834 835 834 835 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 915 917 915 917 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sub>
###xml 1187 1188 1186 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">z</italic>
###xml 401 405 <span type="species:ncbi:9925">goat</span>
###xml 477 482 <span type="species:ncbi:10090">mouse</span>
###xml 527 532 <span type="species:ncbi:10090">mouse</span>
###xml 600 605 <span type="species:ncbi:10090">mouse</span>
Indirect immunofluorescence was carried out on A375 cells fixed and permeabilized with 0.1% glutaraldehyde, PBS and 0.1% Triton X-100, PBS and on retinal pigment epithelial (RPE) cells fixed and permeabilized with 4% formalin (Sigma) and 0.1% Triton X-100, PBS. Coverslips were blocked with 5% BSA and incubated with anti-MRDI (1:1000), anti-neuronal Wiskott-Aldrich syndrome protein (N-WASP) (1:200, goat; sc-10122(D15), Santa Cruz Biotechnology, Inc.), anti-vinculin (1:500, mouse; HVIN-1, Sigma), anti-FAK-Tyr(P)397 (1:500, mouse; BD Transduction Laboratories), or anti-paxillin-Tyr(P)118 (1:500, mouse; BD Transduction Laboratories) followed by secondary antibodies coupled to Alexa Fluor 488 or Alexa Fluor 592 (Molecular Probes). For F-actin staining, cells fixed with 4% formalin were incubated with rhodamine phalloidin (3.3 nm; Molecular Probes). Membrane staining was carried out using CellTracker CM-DiIC18 (1 mug/ml; Molecular Probes) as a fluorescent lipophilic marker. Cells were monitored with a Zeiss Axioplan II fluorescence microscope outfitted with an apochromatic lens with a high numerical aperture (1.4) and a corrective lens element for spherical aberrations. The z axis resolution of this instrument is approximately400 nm. Data were collected using a Cooke SensiCam charge-coupled device camera and SlideBook software (Intelligent Imaging Innovations).
###end p 24
###begin p 25
###xml 412 418 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
Live cell imaging was performed on an Olympus IX81 inverted microscope equipped with a heated stage. Images were acquired with an ORCA-100 digital camera (Hamamatsu) and analyzed with Slidebook software. Cells were grown on collagen-coated coverslips in RPMI, 10% FBS and serum-starved for 1 h. Serum was added to a final concentration of 10%, and cells were monitored for 60 min. ImageJ was used to track cells versus time.
###end p 25
###begin title 26
Immunohistochemistry
###end title 26
###begin p 27
###xml 893 894 881 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 48 55 <span type="species:ncbi:9606">patient</span>
###xml 338 344 <span type="species:ncbi:9986">rabbit</span>
###xml 345 356 <span type="species:ncbi:3704">horseradish</span>
###xml 973 977 <span type="species:ncbi:10090">mice</span>
###xml 994 998 <span type="species:ncbi:10090">mice</span>
Sections from formalin-fixed, paraffin-embedded patient biopsies were deparaffinized, rehydrated, and treated with antigen retrieval solution (Dako Cytomation) in a decloaking chamber (Biocare Medical) first at 120 degreesC for 30 s and then at 85 degreesC for 10 s. Sections were stained with anti-MRDI (1:200 overnight followed by anti-rabbit horseradish peroxidase and developed with 3,3'-diaminobenzidine (Dako Cytomation Envision Elite). Specimens were then counterstained with hematoxylin and azure B (Sigma). Negative controls with antibody preincubated with 0.1 mg/ml peptide were used to verify low background staining. A tissue microarray (YMTA 33, Yale tissue microarray facility, Yale University, New Haven, CT) containing 200 specimens, including melanomas from organs other than skin, was processed in a similar manner. Xenograft tissues were prepared by injecting A375 cells (106 cells) intradermally to the right posterior flank of female NIH athymic nu/nu mice. After 6 weeks, mice were sacrificed by cervical dislocation, and tumors were dissected, fixed in formalin, embedded, and processed for immunohistochemistry with anti-MRDI + diaminobenzidine.
###end p 27
###begin title 28
Cell Invasion
###end title 28
###begin p 29
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 633 639 <span type="species:ncbi:9913">bovine</span>
Cells were transfected with RNAi oligonucleotide to suppress MRDI protein expression, and 5 x 104 cells were plated onto upper chambers of a Matrigel assay system (24-well; BD Biosciences) using serum-free RPMI in upper chambers and 10% FBS, RPMI in lower chambers. After 24 h, invaded cells on the lower chamber membrane surfaces were fixed, visualized with Wright-Giemsa stain (Sigma), and counted. Spheroid assays were carried out as described by Smalley et al. (45). Melanoma cells were plated on 1.5% Noble agar for 3-5 days. Spheroids were collected and centrifuged (3000 rpm) to remove medium; gently resuspended in 2.5 mg/ml bovine dermal collagen (PureCol, INAMED, Leimuiden, Netherlands) in RPMI, 10% FBS; and overlaid on a presolidified layer of the same collagen solution. The collagen/cell suspension was allowed to solidify for 1 h and then overlaid with RPMI, 10% FBS. Spheroids were grown for 10 days after implanting to monitor 3D growth and invasion into collagen, and images were collected by phase microscopy.
###end p 29
###begin title 30
Enzyme Assays
###end title 30
###begin p 31
###xml 69 70 69 70 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 119 120 118 119 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 130 131 129 130 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 135 136 134 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 151 152 150 151 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 163 164 162 163 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 271 272 263 264 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 454 455 446 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 608 610 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 600 606 <span type="species:ncbi:43335">Abeles</span>
Methylthioribose 1-phosphate (MTR-1-P) was produced by incubating 1 mm MTA with methylthioadenosine phosphorylase (1 mum) in 100 mm NaPi, pH 7.4, 0.5 mm DTT, 0.5 mm EDTA for 16.5 h at 37 degreesC. Reactions were conducted in the presence or absence of purified MRDI (1 mum) to assay conversion of MTR-1-P to methylthioribulose 1-phosphate (MTRu-1-P). Reactions were clarified by ultrafiltration to remove proteins, and reaction products were examined by 1H NMR (Varian 600-MHz spectrometer). Chemical shift assignments were matched to those described for purified MTR-1-P and MTRu-1-P by Furfine and Abeles (31).
###end p 31
###begin title 32
Rho GTPase Assays
###end title 32
###begin p 33
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 176 177 170 171 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 254 255 248 249 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 266 267 260 261 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 272 273 266 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 320 321 312 313 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Rho-GTP was assayed by adapting published protocols (32) to reduce background and enhance signal to noise. Proteins were extracted for 3 min at 4 degreesC in lysis buffer (50 mm Tris-HCl, pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 0.65 m NaCl, 10 mm MgCl2, 10 mug/ml leupeptin, 10 mug/ml aprotinin, 1 mm PMSF; 0.7 ml). Clarified extracts were incubated for 20 min at 4 degreesC with glutathione-Sepharose (Amersham Biosciences) coupled to bacterially expressed GST-RBD (Rho binding domain of rhotekin; 30 mug) and then washed five times with lysis buffer. Samples precipitated from 200 mug of total protein were resolved by 12.5% SDS-PAGE, and bound RhoA-GTP and RhoC-GTP were visualized by Western blotting with anti-RhoA or -RhoC antibodies.
###end p 33
###begin title 34
RESULTS
###end title 34
###begin title 35

###end title 35
###begin title 36

###end title 36
###begin title 37
Stage-specific Activation of RhoA in Melanoma Cell Lines
###end title 37
###begin p 38
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 253 253 253 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19"/>
###xml 253 253 253 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20"/>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 575 581 575 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 747 752 <span type="species:ncbi:9606">human</span>
We monitored the activation of RhoA in 20 melanocyte or melanoma cell lines cultured from radial growth phase, vertical growth phase, or metastatic tumors that had been catalogued with respect to tumor pathology, tumorigenicity, and soft agar growth (18-21). The activity state of RhoA from cell lysates was measured by GTP binding and subsequent association with GST-RBD. The highest frequency of activated RhoA was observed in cells of metastatic origin where six of eight metastatic cell lines showed elevated RhoA-GTP in a manner uncorrelated with total RhoA expression (Fig. 1). Enhanced specific activity was verified by normalizing RhoA-GTP signal to total RhoA protein (). The results indicate that RhoA is activated in cells derived from human metastatic melanomas.
###end p 38
###begin p 39
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stage-specific activation of RhoA in melanoma cells.</bold>
###xml 301 304 297 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RGP</italic>
###xml 327 330 323 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VGP</italic>
###xml 355 361 351 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M'cyte</italic>
Stage-specific activation of RhoA in melanoma cells. RhoA activation was measured by Rho-GTP binding to GST-RBD. Western blots show levels of RhoA-GTP bound to GST-RBD in pulldown assays and RhoA and gamma-tubulin in total cell lysates. Similar results were observed in three independent experiments. RGP, radial growth phase; VGP, vertical growth phase; M'cyte, melanocyte.
###end p 39
###begin title 40
A Functional Proteomics Screen for RhoA Pathway Targets
###end title 40
###begin p 41
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 993 993 993 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34"/>
###xml 993 993 993 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35"/>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 226 233 <span type="species:ncbi:9606">patient</span>
###xml 341 350 <span type="species:ncbi:10090">nude mice</span>
To identify targets downstream of RhoA, constitutively active mutant RhoA-V14 was expressed by adenoviral delivery into WM35, an early stage nonmetastatic cell line derived from a primary superficial spreading melanoma from a patient with no metastasis (18). WM35 cells grow slowly, form few colonies in soft agar, and do not form tumors in nude mice. Proteins in soluble lysates were resolved by 2DE and visualized by silver staining, monitoring proteins whose intensities changed reproducibly by >1.5-fold following RhoA-V14 expression compared with control cells infected with empty adenovirus. The expression of RhoA-V14 led to cell contraction and rounding (). Five proteins showing features that were reproducibly altered in response to RhoA were identified by in-gel digestion followed by peptide mass mapping and peptide sequencing by mass spectrometry (). Of these, two (tropomyosin and protein phosphatase 1B) were characterized previously as downstream targets of RhoA signaling (33-36). Thus, three novel cellular targets of RhoA signaling were identified by the screen.
###end p 41
###begin p 42
###xml 462 468 462 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 468 469 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 810 816 810 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 816 817 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 995 1001 995 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 1001 1002 1001 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 780 785 <span type="species:ncbi:9606">human</span>
We next asked which of these proteins were functional RhoA targets during melanoma progression. We hypothesized that proteins that were functional mediators of RhoA signaling would be regulated across many cell lines in a manner correlating with the activation state of RhoA. The five proteins found to be responsive to RhoA were examined by 2DE in 14 melanocyte and melanoma cell lines, comparing their signal intensities with those in unstimulated WM35 cells (Fig. 2A). Only three of the proteins responsive to RhoA in WM35 cells showed 2DE signals in other melanoma cell lines, and of these, only one showed increased intensity in metastatic cells consistent with the pattern of RhoA activation (supplemental Fig. ). MGC3207 is a previously uncharacterized gene annotated as a human "hypothetical protein" (Fig. 2B). Intensities of features from MGC3207 were elevated in WM35 cells stimulated with RhoA and in metastatic lines (A375, HS294T, and Lu451) compared with unstimulated WM35 cells (Fig. 2C) commensurate with a potential change in protein expression. We hypothesized that MGC3207 might function to regulate RhoA signaling responses important for metastatic cell behavior. Based on its characterization below, we refer to this protein throughout as MRDI.
###end p 42
###begin p 43
###xml 0 48 0 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A functional proteomics screen for RhoA targets.</bold>
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Step 1</italic>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Step 2</italic>
###xml 353 354 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 437 447 437 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">underlined</italic>
###xml 470 475 470 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">boxed</italic>
###xml 478 479 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 604 614 604 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Arrowheads</italic>
###xml 660 664 660 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">open</italic>
###xml 735 741 735 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">closed</italic>
###xml 744 747 744 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RGP</italic>
###xml 770 773 770 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VGP</italic>
###xml 368 373 <span type="species:ncbi:9606">human</span>
A functional proteomics screen for RhoA targets.A, outline of the experimental strategy for identifying proteins responsive to RhoA. Step 1, protein responses to RhoA-V14 are profiled in WM35 cells by 2DE to identify pathway targets. Step 2, these targets are examined in other melanoma cell lines to identify those that correlate with RhoA activation. B, sequence of human MGC3207 indicating peptides observed by peptide mass matching (underlined) or MS/MS sequencing (boxed). C, 2DE images showing MGC3207 protein changes responsive to RhoA in WM35 cells and across melanocyte and melanoma cell lines. Arrowheads show protein intensities that are unaltered (open) or altered in the same direction as those induced by RhoA signaling (closed). RGP, radial growth phase; VGP, vertical growth phase.
###end p 43
###begin title 44
MRDI Is Induced by Constitutive RhoA Signaling
###end title 44
###begin p 45
###xml 223 229 223 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
Peptide antibodies were produced to characterize MRDI expression. Western blotting confirmed that expression of the expected 40-kDa protein was elevated in metastatic lines in a manner that correlated with RhoA activation (Fig. 3A). MRDI showed variable gel mobility in different lines; we ascribed this to differences in covalent modification because 2DE blots showed that MRDI separated into three spots with similar mass and varying pI, indicating the existence of at least two post-translationally modified forms (). However, all forms were increased in response to RhoA, and we were unable to detect evidence for regulated covalent modification.
###end p 45
###begin p 46
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRDI is induced by RhoA and mediates RhoA-dependent cell invasion.</bold>
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;E</italic>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 290 296 290 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 296 297 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 353 354 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 578 587 573 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 1&#8211;4</italic>
###xml 666 675 661 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 5&#8211;8</italic>
###xml 678 679 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 777 778 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 976 977 971 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 1239 1242 1234 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPA</italic>
###xml 1252 1255 1247 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F&#8211;H</italic>
###xml 1286 1287 1281 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 1398 1399 1393 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1627 1628 1620 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1635 1636 1628 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</italic>
###xml 1766 1769 1759 1762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RGP</italic>
###xml 1792 1795 1785 1788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VGP</italic>
###xml 497 500 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 622 625 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 713 716 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
MRDI is induced by RhoA and mediates RhoA-dependent cell invasion.A-E, Western blots demonstrate that RhoA induces expression of MRDI. A, blots probed with anti-MRDI show elevated protein levels in metastatic cell lines with constitutive RhoA activity. RhoA-GTP blots are from the image in Fig. 1A. Loading controls show alpha-tubulin in total lysates. B, RhoA is necessary for MRDI induction. Extracts (5 mug) were probed with anti-MRDI, examining WM35 cells treated by adenoviral delivery of Ad-CMV, Ad-Rac1-V12, or Ad-RhoA-V14 or pretreated with Y27632 prior to Ad-RhoA-V14 (lanes 1-4). A375 cells were treated with Ad-CMV, Ad-DN-Rac1, C3 transferase, or Y27632 (lanes 5-8). C, A375 cells were treated with Ad-CMV or Ad-DN-RhoA-N19, and lysates were blotted with anti-MRDI. D, A375 cells were treated with RNAi for 48 h to inhibit expression of RhoA or RhoC, and lysates were blotted with anti-MRDI. Anti-RhoA or anti-RhoC Westerns demonstrate selective knockdown by RNAi. E, control or RhoC-expressing WM35 cells were examined for expression of MRDI and RhoC, and RhoC-GTP was assayed by GST-rhotekin pulldown assays. RhoC overexpression and activation had little effect on MRDI compared with cells treated with lysophosphatidic acid (LPA) (24 h). F-H, MRDI promotes cell invasion. F, RNAi knockdown of MRDI in metastatic melanoma A375 and HS294T cells inhibits cell invasion through Matrigel. G, invasion is suppressed in A375 cells treated with four different MRDI-RNAi oligonucleotide sequences, singly or in combination, but not in cells treated with lamin A/C-RNAi (48-h transfection). Values represent mean +/- S.D. (n = 3). H, cell invasion depends on Rho signaling. Invasion is reduced in A375 cells treated with RhoA-RNAi, RhoC-RNAi, or C3 transferase. RGP, radial growth phase; VGP, vertical growth phase.
###end p 46
###begin p 47
###xml 147 153 147 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 153 154 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 290 296 290 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 391 397 391 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
MRDI protein expression was elevated in premetastatic (WM35) cells expressing RhoA-V14 but not Rac-V12, indicating its selective response to RhoA (Fig. 3B). Its expression in metastatic (A375) cells was reduced by inhibiting RhoA-GTP with C3 transferase or dominant negative (DN) RhoA-N19 (Fig. 3, B and C). Likewise RhoA knockdown by RNAi resulted in partial inhibition of MRDI expression (Fig. 3D), although because cell viability was compromised by RhoA-RNAi, the experiment could not be carried out long enough for complete protein turnover. Taken together, the results demonstrate that RhoA activation is necessary for elevated MRDI expression. Induction of MRDI was blocked by inhibiting transcription with actinomycin D or inhibiting protein synthesis with cycloheximide, indicating that RhoA-dependent expression is most likely regulated transcriptionally ().
###end p 47
###begin p 48
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 335 341 335 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 341 342 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 421 427 421 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 427 428 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 662 668 662 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 668 669 668 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 837 845 837 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
We next examined MRDI expression in WM35 cells stably transfected with RhoC. RhoC overexpression in melanoma cell lines enhances morphological transformation, cell survival, and cell invasion (4, 37). However, RhoC led to little or no induction of MRDI under conditions where GTP loading was confirmed by GST-rhotekin pulldown assays (Fig. 3E). Selective knockdown of RhoC by RNAi resulted in little suppression of MRDI (Fig. 3D). We conclude that MRDI is primarily induced by RhoA and less responsive to RhoC in nonmetastatic and metastatic cells. Pretreating cells with the Rho-activated kinase inhibitor Y27632 did not alter RhoA-dependent induction of MRDI (Fig. 3B), indicating that its expression is not regulated by the RhoA-Rho-activated kinase branch point. Positive controls confirmed that Y27632 inhibited Rho kinase activity in vitro and suppressed Rho signaling in melanoma cells ().
###end p 48
###begin title 49
MRDI Promotes Cell Invasion
###end title 49
###begin p 50
###xml 184 190 184 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 342 348 342 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 348 349 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 629 635 629 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 635 636 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</italic>
We next assayed cell invasion through Matrigel and observed significant repression of invasion in metastatic cell lines (A375 and HS294T) when MRDI expression was inhibited with RNAi (Fig. 3F). The specificity of inhibition was confirmed by four different MRDI-RNAi oligonucleotides with no effect using lamin A/C-RNAi as a negative control (Fig. 3G). Invasion was also repressed by MRDI knockdown in metastatic WM239A cells but was unaffected in nonmetastatic cells in which MRDI expression was normally low (). RNAi knockdown of either RhoA or RhoC or treatment of cells with C3 transferase also caused repression of invasion (Fig. 3H). The results show that Rho promotes invasion in metastatic melanoma cell lines and indicate that MRDI mediates Rho signaling to cell invasion. Thus, MRDI is a functional target of RhoA, which controls downstream responses to this pathway.
###end p 50
###begin title 51
###xml 49 54 <span type="species:ncbi:9606">Human</span>
Cytoplasmic and Membrane Localization of MRDI in Human Melanomas
###end title 51
###begin p 52
###xml 624 630 624 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 630 631 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 770 776 770 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 776 777 776 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 15 20 <span type="species:ncbi:9606">human</span>
Examination of human melanoma specimens revealed correlations between tumor stage and subcellular localization of MRDI. Biopsies of atypical/dysplastic nevi, primary melanomas, and metastatic melanomas were immunostained with anti-MRDI antibody, counterstained with hematoxylin-azure B, and observed by light microscopy. MRDI immunoreactivity was observed within cells of melanocyte origin, keratinocytes, endothelial cells, and infiltrating lymphocytes. Importantly the immunoreactivity in nontumorigenic melanocytes located within atypical or dysplastic nevi was mostly nuclear and often accentuated at nuclear membranes (Fig. 4A and ). In contrast, primary and metastatic melanomas within skin often showed elevated MRDI immunoreactivity in cytoplasmic compartments (Fig. 4B and ). Immunoreactivity was also examined in metastatic tumors taken from lymph node and other non-skin tissues. Although the intensity of immunostaining was variable in these samples, metastatic melanomas generally showed higher MRDI localization within cytoplasmic compartments compared with early stage melanomas (). Antibody specificity was confirmed by peptide competition controls (). Together the results suggest that cytoplasmic pools of MRDI increase whereas nuclear pools decrease during advanced stages of disease.
###end p 52
###begin p 53
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRDI localizes to membranes and cell protrusions.</bold>
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 55 56 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 230 231 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 242 249 242 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 314 319 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">inset</italic>
###xml 399 409 399 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">arrowheads</italic>
###xml 412 413 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 539 549 539 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">arrowheads</italic>
###xml 552 553 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 877 887 876 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
###xml 890 891 889 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 977 979 976 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ab</italic>
###xml 992 994 991 993 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sub>
###xml 996 1002 995 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CM-dil</italic>
###xml 1202 1212 1200 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
###xml 1215 1216 1213 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 528 537 <span type="species:ncbi:10090">nude mice</span>
MRDI localizes to membranes and cell protrusions.A and B, MRDI localization correlates with tumor grade in human melanoma specimens. A, junctional compound nevus shows nuclear localization but little cytoplasmic immunoreactivity. B, melanoma in situ shows MRDI immunoreactivity localized to cytoplasmic pools. The inset at higher magnification illustrates membrane accentuation of immunoreactivity (arrowheads). C, MRDI immunostaining shows membrane accentuation between cells in xenograft tumors of A375 cells grown in athymic nude mice (arrowheads). D, MRDI localizes to cell protrusions in cultured A375 cells when probing endogenous MRDI with anti-MRDI (1:3000). Cells treated with MRDI-RNAi show loss of reactivity at the membrane leading edge and protrusions and partial loss of nuclear staining. Western blots of lysates (5 mug) probed with anti-MRDI confirm knockdown (left panel). E, RPE cells transfected with MRDI or empty vector and probed with anti-MRDI antibody (Ab) and CM-DiIC18 (CM-dil) show localization of MRDI at the membrane periphery and leading edge. Western blots of lysates (20 mug) show low protein expression in untransfected cells and elevated expression upon transfection (left panel). F, indirect immunofluorescence of RPE cells shows colocalization of MRDI with N-WASP at the membrane leading edge.
###end p 53
###begin p 54
###xml 164 170 164 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 170 171 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">inset</italic>
###xml 180 190 180 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">arrowheads</italic>
###xml 329 335 329 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 335 336 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 338 348 338 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">arrowheads</italic>
###xml 522 528 522 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 528 529 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 667 673 667 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 673 674 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
Interestingly MRDI immunoreactivity within primary and metastatic tumors was often observed to be accentuated at membrane regions where cells contacted each other (Fig. 4B, inset, arrowheads). Similar patterns were observed in xenograft tissues grown by subcutaneous injection of metastatic A375 cells into immunodeficient mice (Fig. 4C, arrowheads). Consistent with this, immunocytochemistry of cultured A375 cells showed that MRDI localized to membrane protrusions at the cell periphery as well as within the cell body (Fig. 4D). All of the reactivity at cell protrusions but only part of the cell body reactivity was reduced upon blocking MRDI expression by RNAi (Fig. 4D) with similar effects observed using peptide competition (data not shown), suggesting that nuclear staining partly reflects nonspecific reactivity.
###end p 54
###begin p 55
###xml 277 279 277 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sub>
###xml 281 287 281 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 287 288 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 334 340 334 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 340 341 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
Similar results were observed upon transient expression of MRDI into non-melanoma cells that express low amounts of protein endogenously. Immunostaining of RPE cells showed transfected MRDI at the membrane leading edge, colocalizing with the fluorescent membrane tracer CM-DiIC18 (Fig. 4E). In addition, MRDI colocalized with N-WASP (Fig. 4F and ), a ubiquitous adaptor protein that mediates agonist-induced F-actin nucleation and polymerization by binding Arp2/3 (38). No overlap was observed between MRDI and actin stress fibers or the focal adhesion markers vinculin, FAK, and paxillin (). Thus, the cellular localization of MRDI reflects membrane accentuation in melanoma cells in both tissues and cultured cells.
###end p 55
###begin title 56
MRDI Promotes Cell Movement and Tyrosine Phosphorylation of Focal Adhesion Kinase
###end title 56
###begin p 57
###xml 560 566 560 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 566 567 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
Given its function in cell invasion, the membrane localization of MRDI suggested potential control of events involved in cell motility and/or cell-substrate interactions. Therefore, cells from a metastatic tumor (A375) were examined by live cell imaging before and after knockdown of MRDI by RNAi, and cell motility was monitored by tracking nuclear movement for 60 min. Whereas control cells showed elevated motility following serum stimulation, cells in which MRDI was inhibited became flatter after serum addition and showed significantly reduced movement (Fig. 5A and ). Scoring cells across several experiments, MRDI knockdown caused a 2-fold decrease in the number of cells that migrated by more than one nuclear diameter in 60 min (approximately25 mum/h) and a 2.8-fold decrease in cells migrating by more than two nuclear diameters (approximately50 mum/h) compared with controls.
###end p 57
###begin p 58
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRDI modulates cell motility, FAK phosphorylation, and stress fiber formation.</bold>
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 330 341 330 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Right panel</italic>
###xml 468 469 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</italic>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</italic>
###xml 520 521 520 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 603 604 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 621 622 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 634 635 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 647 650 645 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">397</sup>
###xml 705 712 703 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 1</italic>
###xml 717 718 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 777 784 775 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 3</italic>
###xml 789 790 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 806 813 804 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 5</italic>
###xml 818 819 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</italic>
###xml 879 880 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
MRDI modulates cell motility, FAK phosphorylation, and stress fiber formation.A, live cell images of A375 cells treated with control scrambled oligonucleotide or MRDI-RNAi show decreased cell movement following MRDI knockdown. Images are taken at t = 0 after serum addition, and traces show nuclear movement over the next 60 min. Right panel, summary of several biological replicates quantifying percentages of control and MRDI-RNAi cells that move by less than one ("0"), between one and two ("1"), and more than two ("2") nuclear diameters in 60 min. Values show mean +/- S.E. (number of experiments, n = 9 control and n = 8 RNAi). B, FAK-Tyr(P)397 is up-regulated in WM35 cells expressing Ad-RhoA-V14 (lanes 1 and 2) and inhibited in A375 cells treated with C3 transferase (lanes 3 and 4) or MRDI-RNAi (lanes 5 and 6). In contrast, total FAK protein expression is unaffected. C, MRDI knockdown enhances actin polymerization. A375 cells were transfected for 48 h with or without MRDI-RNAi and observed following phalloidin staining. Two representative cells are shown in each experiment.
###end p 58
###begin p 59
###xml 251 254 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">397</sup>
###xml 256 262 256 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 355 358 355 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">397</sup>
###xml 509 512 509 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">397</sup>
###xml 693 696 693 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1114 1120 1114 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 1120 1121 1120 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
Finally we examined the influence of MRDI on biochemical events regulated by RhoA. In a nonmetastatic melanoma cell line in which the activity of RhoA is normally low (WM35) expression of RhoA-V14 caused elevated tyrosine phosphorylation of FAK at Tyr397 (Fig. 5B). Moreover in a metastatic cell line in which RhoA is normally activated (A375), FAK-Tyr(P)397 was constitutively high and was reduced upon inhibiting RhoA with C3 transferase. Importantly inhibiting MRDI expression by RNAi eliminated FAK-Tyr(P)397 in metastatic cells. This demonstrates that FAK autophosphorylation is RhoA-dependent and that MRDI is required for this regulation. Previous studies have shown that cells from FAK-/- mice lose motility and cannot be rescued with mutant FAK-Y397F because they fail to disassemble focal adhesion complexes (14). We therefore hypothesized that MRDI might enhance focal adhesion turnover, which would repress stress fiber formation. We examined this prediction and found that knockdown of MRDI in cells from a metastatic tumor caused a significant increase in actin stress fibers compared with controls (Fig. 5C). Taken together, the results suggest that MRDI promotes cell invasion in response to constitutive RhoA activation in part by promoting FAK tyrosine phosphorylation and stress fiber turnover.
###end p 59
###begin title 60
MRDI Has Dual Function as a Metabolic Enzyme
###end title 60
###begin p 61
###xml 361 363 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 791 792 759 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 813 814 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 878 879 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 951 953 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 1023 1029 991 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 1029 1030 997 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1098 1115 1066 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus subtilis</italic>
###xml 1117 1138 1085 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Klebsiella pneumoniae</italic>
###xml 1144 1168 1112 1136 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Saccharomyces cerevisiae</named-content>
###xml 1225 1227 1193 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 1227 1227 1195 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42"/>
###xml 1228 1230 1196 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 1033 1038 <span type="species:ncbi:9606">Human</span>
###xml 1098 1115 <span type="species:ncbi:1423">Bacillus subtilis</span>
###xml 1117 1138 <span type="species:ncbi:573">Klebsiella pneumoniae</span>
###xml 1144 1168 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 1293 1298 <span type="species:ncbi:9606">human</span>
MRDI has never been characterized in human systems and in the human database is often annotated as a hypothetical protein. Sequence alignments showed that MRDI belongs to a protein family of translational initiation factors, sharing a motif of 25 residues (residues 322-346) with alpha, beta, and delta subunits of the guanine nucleotide exchange factor eIF2B (39). However, this association yielded little insight into protein function because exchange factor activity is catalyzed by the gamma/epsilon subunits of eIF2B, whereas the functions of the alpha/beta/delta subunits are unknown. Further examination showed that a subset of this family contains genes unrelated to translational initiation that instead function in amino acid salvage (). During polyamine synthesis, decarboxylated S-adenosylmethionine (S-AdoMet) is converted to MTA, which cannot be converted back to S-AdoMet and must instead be catabolized to its end product, methionine (40). Thus, the pathway of MTA catabolism results in methionine salvage (Fig. 6A). Human MRDI appears to be an ortholog of enzymes characterized in Bacillus subtilis, Klebsiella pneumoniae, and Saccharomyces cerevisiae that catalyze the isomerization of MTR-1-P to MTRu-1-P (41-43). This suggested that MRDI might serve as an isomerase in the human methionine salvage pathway, which has never been fully elucidated.
###end p 61
###begin p 62
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRDI is a methylthioribose-1-phosphate isomerase.</bold>
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 142 143 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 220 223 220 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B&#8211;E</italic>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 327 335 327 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 362 363 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 378 379 378 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 536 537 536 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 554 555 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 584 587 584 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a&#8211;f</italic>
###xml 592 593 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 598 599 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 635 636 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
MRDI is a methylthioribose-1-phosphate isomerase.A, enzymatic steps in the methionine salvage pathway. Following conversion of decarboxylated S-AdoMet to MTA during polyamine synthesis, MTA is catabolized to methionine. B-E, recombinant purified MRDI shows MTR-1-P isomerase enzymatic activity. 1H NMR spectra, collected after in vitro reactions in the absence (B) or presence (C) of wild type MRDI, show that MRDI catalyzes the conversion of MTR-1-P to MTRu-1-P. In contrast, catalytic turnover is absent in reactions with MRDI-C168S (D) or MRDI-D248A (E) mutants. Peak assignments (a-f) in B and C correspond to protons indicated in A.
###end p 62
###begin p 63
###xml 103 104 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 212 218 212 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 218 219 218 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 391 397 391 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 490 498 490 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
To test this hypothesis, MTR-1-P was produced enzymatically from MTA using purified MTA phosphorylase. 1H NMR confirmed the presence of MTR-1-P by matching chemical shift peaks to those assigned previously (31) (Fig. 6B). Incubation of MTR-1-P with purified recombinant MRDI led to the reduction of substrate peak intensities and the new appearance of peaks assigned previously to MTRu-1-P (Fig. 6C). This confirmed that MRDI has enzymatic activity as a MTR-1-P isomerase in catalyzing the in vitro conversion of the substrate, MTR-1-P, to its product, MTRu-1-P.
###end p 63
###begin p 64
###xml 66 77 66 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B. subtilis</italic>
###xml 82 95 82 95 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">S. cerevisiae</named-content>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 155 168 155 168 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">S. cerevisiae</named-content>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 424 435 424 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B. subtilis</italic>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 756 759 756 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">168</sup>
###xml 767 770 767 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">248</sup>
###xml 886 894 886 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 974 980 974 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 982 983 982 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 988 989 988 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 1011 1014 1011 1014 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">168</sup>
###xml 1022 1025 1022 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">248</sup>
###xml 66 77 <span type="species:ncbi:1423">B. subtilis</span>
###xml 82 95 <span type="species:ncbi:4932">S. cerevisiae</span>
###xml 155 168 <span type="species:ncbi:4932">S. cerevisiae</span>
###xml 424 435 <span type="species:ncbi:1423">B. subtilis</span>
###xml 774 779 <span type="species:ncbi:9606">human</span>
###xml 847 852 <span type="species:ncbi:9606">human</span>
Previous x-ray structure determinations of MTR-1-P isomerase from B. subtilis and S. cerevisiae each revealed a homodimer of 40-kDa subunits (43, 44). The S. cerevisiae structure (Protein Data Bank code ; Ref. 43) showed well ordered sulfate ions present at the interface between two domains in each monomer that were proposed to occupy the binding site for the phosphate moiety of MTR-1-P in the enzyme active site (). The B. subtilis structure confirmed cocrystallization of the product, MTRu-1-P, within this site (Protein Data Bank code ; Ref. 44). The residues coordinating the sulfate ion form an interface between solvent and a deep hydrophobic pocket containing Asp and Cys residues that are conserved throughout the subfamily and correspond to Cys168 and Asp248 in human MRDI (). We therefore constructed the mutations C168S and D248A in human MRDI and tested their effects on in vitro isomerase activity. Either mutation inhibited turnover of MTR-1-P to MTRu-1-P (Fig. 6, D and E). This identified Cys168 and Asp248 as active site residues required for MTR-1-P isomerase catalytic activity.
###end p 64
###begin p 65
###xml 248 254 248 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 254 255 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 385 391 385 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 391 392 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 614 620 614 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 622 623 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 628 629 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 727 733 727 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 733 734 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 235 240 <span type="species:ncbi:9606">human</span>
###xml 792 797 <span type="species:ncbi:9606">human</span>
To test the cellular function of MRDI in methionine salvage, we measured the dependence of cell growth on MTA. Cells incubated in medium lacking methionine failed to grow, consistent with a requirement for this essential amino acid in human cells (Fig. 7A). In contrast, methionine-free medium supplemented with MTA supported cell growth to levels reaching 25% of that in full medium (Fig. 7A and ). Importantly stable knockdown of MRDI completely prevented cell growth in the presence of MTA, and the phenotype was rescued by stable expression of MRDI-WT harboring silent mutations to bypass the shRNA knockdown (Fig. 7, A and B). In contrast, expression of MRDI-C168S or -D248A mutants failed to rescue the growth phenotype (Fig. 7B). This confirms that MTA is a precursor of methionine in human cells and that the catalytic activity of MRDI as an MTR-1-P isomerase is necessary for metabolic flux through the methionine salvage pathway.
###end p 65
###begin p 66
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Catalytic activity of MRDI is required for methionine salvage but not cell invasion.</bold>
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 261 262 260 261 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 444 445 443 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 732 735 725 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C&#8211;H</italic>
Catalytic activity of MRDI is required for methionine salvage but not cell invasion.A, A375 cells grown in the absence of methionine (▲) show growth arrest due to lack of an essential amino acid in the medium. This is partially rescued by incubation with 100 mum MTA in control cells (●). MTA fails to rescue growth in cells in which MRDI expression is stably inhibited by shRNA (♢), demonstrating a requirement for MRDI in methionine salvage. B, MRDI-shRNA knockdown cells were grown in the presence of MTA and the absence of methionine. Growth was rescued by add-back expression of MRDI-WT (diamond) but not C168S (■) or D248A (o) mutants, indicating that MRDI catalytic activity is needed for cell growth via methionine salvage. C-H, A375 cells grown as spheroids show suppression of invasion into 3D collagen matrix upon stable knockdown of MRDI with shRNA. The invasion phenotype is rescued equally well by MRDI-WT, -C168S, and -D248A, indicating that catalytic activity is not required for cell invasion.
###end p 66
###begin p 67
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 427 433 427 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 435 436 435 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 441 442 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 584 590 584 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 592 593 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 598 599 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 725 731 725 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 733 734 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 739 740 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</italic>
###xml 286 291 <span type="species:ncbi:9606">human</span>
Finally we asked whether the catalytic function of MRDI is relevant to its role in cell invasion. A375 cells were grown as spheroid colonies embedded in collagen, an assay that mimics 3D growth and invasion by melanoma cells surrounded by the main extracellular matrix protein found in human dermis (45). Knockdown of endogenous MRDI had no effect on spheroid growth rate but significantly blocked cell invasion into collagen (Fig. 7, C and D). Expression of MRDI-WT in the stable knockdown cells rescued the cell invasion phenotype, confirming the specificity of the shRNA response (Fig. 7, E and F). The key finding was that neither C168S nor D248A mutations affected the ability of MRDI to rescue the knockdown phenotype (Fig. 7, G and H). The results confirm that MRDI promotes melanoma cell invasion in 3D culture and demonstrates that its catalytic activity as an isomerase is not necessary for its function in RhoA signaling and invasion.
###end p 67
###begin title 68
DISCUSSION
###end title 68
###begin p 69
###xml 350 355 <span type="species:ncbi:9606">human</span>
Our study provides novel insights into how the RhoA pathway controls the cancer phenotype of cell invasion. In melanoma cell lines, MRDI represents a novel target of Rho signaling, functioned in cell invasion, and was necessary for autophosphorylation of FAK, a key mediator of focal adhesion turnover. MRDI showed targeting to membranes in advanced human melanoma specimens and localizes at the leading edge of cells in culture. A role in regulating membrane events was also suggested in cultured cells by live cell imaging and findings that link MRDI to FAK phosphorylation and stress fiber destabilization consistent with its role in promoting cell invasion. Taken together, our results suggest that MRDI promotes cell invasion under conditions of RhoA pathway dysregulation by regulating molecular events key to the control of membrane dynamics and cell adhesion. A working model is presented in .
###end p 69
###begin p 70
Our proteomics screening strategy involved profiling protein responses to RhoA activation in cells in which the pathway was normally "off" and then carrying out a second screen to filter for targets uniformly regulated across cell lines in which RhoA was constitutively "on." Only one of the five RhoA targets identified initially in premetastatic cells turned out to be highly correlated with constitutive RhoA activation across many cell lines. The fact that MRDI was validated as a regulator of RhoA-dependent cellular responses and correlated with melanoma stage illustrates the utility of prioritizing functional targets by filtering out bystanders that vary between cells because they have no regulatory function.
###end p 70
###begin p 71
Our study also showed that the activation state of RhoA is differentially elevated in melanoma cell lines derived from metastatic tumors, revealing a role for RhoA signaling that is distinct from the previous characterization of RhoC in promoting melanoma metastases. The results underscore the importance of monitoring Rho-GTP levels given that the pathway activation in metastatic cell lines was not reflected by Rho protein expression. Rho activity assays are not routinely measured in cancer samples because of difficulties in performing GTP binding assays on tissue specimens. Future studies are needed to examine whether MRDI is a useful marker for Rho activation in clinical samples.
###end p 71
###begin p 72
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 838 841 838 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">168</sup>
###xml 849 852 849 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">248</sup>
###xml 1199 1200 1199 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 1310 1312 1310 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 397 403 <span type="species:ncbi:9606">humans</span>
###xml 600 603 <span type="species:ncbi:10116">rat</span>
###xml 872 877 <span type="species:ncbi:9606">human</span>
A completely unexpected finding was that MRDI has promiscuous function, acting both as a metabolic enzyme and a regulator of signal transduction. Enzymatic pathways involved in catabolism of MTA are ancient, having been delineated in bacteria and Archaea where they convert MTRu-1-P to 2-keto-4-methylthiobutyrate as a precursor of methionine (40). In contrast, pathways for methionine salvage in humans are incompletely defined, and many of the enzymes that make up these pathways have not been mapped in mammalian genomes. Thus, metabolic conversion of MTR-1-P to MTRu-1-P has been demonstrated in rat cell extracts (31), but the isomerase responsible for this conversion has not been identified until now. By showing that MRDI catalyzes the conversion of MTR-1-P to MTRu-1-P and demonstrating the dependence of activity on residues Cys168 and Asp248, we identified the human MTR-1-P isomerase as well as confirmed residues in the enzyme active site. By showing that MRDI is required for growth in MTA in methionine-free medium and that growth depends on the Cys and Asp residues, we confirmed that MRDI functions as a necessary component in the pathway for methionine salvage from decarboxylated S-AdoMet. Thus, MRDI joins a handful of metabolic enzymes with "moonlighting" function in signal transduction (46).
###end p 72
###begin p 73
###xml 148 149 148 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 309 311 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 313 315 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 513 515 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 515 515 513 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48"/>
###xml 516 518 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 618 619 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 908 910 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 912 914 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
MTR-1-P isomerase is not the only methionine salvage enzyme to be implicated in cancer. MTA phosphorylase, which catalyzes the conversion of MTA + Pi --> MTR-1-P + adenine, is deficient in many cancer types including melanoma, often accompanying co-deletion in the chromosome 9q21 region with p19INK4/CDKN2A (46, 47). MTA phosphorylase is a target for development of inhibitors, which induce apoptosis in head and neck cancer cells, and loss of enzyme enhances cellular sensitivity to chemotherapeutic compounds (47-49). The mechanisms for cell toxicity have been variously ascribed to suppression of MTA recycling to S-AdoMet via methionine or inhibition of purine salvage initiated by the adenine product of MTA phosphorylase. MTA phosphorylase also has tumor suppressor function in certain cancer cells ascribed to autocrine effects of MTA buildup on growth factor and matrix metalloproteinase induction (50, 51). Our results are in contrast to the example of MTA phosphorylase because we showed unequivocally that MRDI controls cancer cell behavior in a manner that is independent of its catalytic function. We speculate that MRDI elevates cell invasion via protein-protein interactions mediated by surface residues distal to the enzyme active site. Thus, MRDI provides unique evidence that some of the processes regulating control of cell adhesion and motility by signal transduction pathways have evolved from protein scaffolds with ancient metabolic function.
###end p 73
###begin title 74
Supplementary Material
###end title 74
###begin title 75
[Supplemental Data]
###end title 75
###begin p 76
We are indebted to Lucy Ghoda, Indranil Basu, Vern Schramm, Channing Der, Joan Heller Brown, and Amy Abell for reagents and advice with assays and to Emily Anderson, Carrie Croy, and Anastasia Khvorova for help in facilitating RNAi experiments. We also thank Meenhard Herlyn for the gift of FM melanocyte and WM melanoma cell lines and David Rimm and the Yale tissue microarray facility for providing us with access to melanoma tissue microarrays. Finally we thank Richard Shoemaker for invaluable assistance with NMR.
###end p 76
###begin p 77
* This work was supported, in whole or in part, by National Institutes of Health Grants R01-CA118972 (to N. G. A.), R01-AI060841 (to M. C. S.), R01-CA126240 (to K. A. R.), P50-CA058187 (to D. C.), T32-GM008759 (to P. D. T.), F32-CA112847 (to E. S. W.), and F32-CA105796 (to G. M. A.).
###end p 77
###begin p 78
###xml 0 0 0 0 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="sbox.jpg"/>
###xml 0 0 0 0 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><inline-graphic xlink:href="sbox.jpg"/></sup>
 The on-line version of this article (available at ) contains .
###end p 78
###begin p 79
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
1 The abbreviations used are:
###end p 79
###begin p 80
###xml 0 3 0 3 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAK</term>
###xml 3 24 3 24 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="81">focal adhesion kinase</p>
###xml 3 24 3 24 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="81">focal adhesion kinase</p></def>
###xml 0 24 0 24 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>FAK</term><def><p textid="81">focal adhesion kinase</p></def></def-item>
###xml 24 28 24 28 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRDI</term>
###xml 28 63 28 63 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="82">mediator of RhoA-dependent invasion</p>
###xml 28 63 28 63 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="82">mediator of RhoA-dependent invasion</p></def>
###xml 24 63 24 63 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>MRDI</term><def><p textid="82">mediator of RhoA-dependent invasion</p></def></def-item>
###xml 63 67 63 67 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RPMI</term>
###xml 67 83 67 83 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="83">RPMI 1640 medium</p>
###xml 67 83 67 83 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="83">RPMI 1640 medium</p></def>
###xml 63 83 63 83 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>RPMI</term><def><p textid="83">RPMI 1640 medium</p></def></def-item>
###xml 83 86 83 86 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FBS</term>
###xml 86 104 86 104 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="84">fetal bovine serum</p>
###xml 86 104 86 104 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="84">fetal bovine serum</p></def>
###xml 83 104 83 104 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>FBS</term><def><p textid="84">fetal bovine serum</p></def></def-item>
###xml 104 107 104 107 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2DE</term>
###xml 107 138 107 138 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="85">two-dimensional electrophoresis</p>
###xml 107 138 107 138 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="85">two-dimensional electrophoresis</p></def>
###xml 104 138 104 138 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>2DE</term><def><p textid="85">two-dimensional electrophoresis</p></def></def-item>
###xml 138 141 138 141 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTA</term>
###xml 141 160 141 160 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="86">methylthioadenosine</p>
###xml 141 160 141 160 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="86">methylthioadenosine</p></def>
###xml 138 160 138 160 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>MTA</term><def><p textid="86">methylthioadenosine</p></def></def-item>
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 160 168 160 168 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>S</italic>-AdoMet</term>
###xml 168 169 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 168 188 168 188 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="87"><italic>S</italic>-adenosylmethionine</p>
###xml 168 188 168 188 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="87"><italic>S</italic>-adenosylmethionine</p></def>
###xml 160 188 160 188 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term><italic>S</italic>-AdoMet</term><def><p textid="87"><italic>S</italic>-adenosylmethionine</p></def></def-item>
###xml 188 192 188 192 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNAi</term>
###xml 192 208 192 208 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="88">RNA interference</p>
###xml 192 208 192 208 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="88">RNA interference</p></def>
###xml 188 208 188 208 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>RNAi</term><def><p textid="88">RNA interference</p></def></def-item>
###xml 208 213 208 213 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">shRNA</term>
###xml 213 230 213 230 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="89">short hairpin RNA</p>
###xml 213 230 213 230 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="89">short hairpin RNA</p></def>
###xml 208 230 208 230 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>shRNA</term><def><p textid="89">short hairpin RNA</p></def></def-item>
###xml 230 233 230 233 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CMV</term>
###xml 233 248 233 248 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="90">cytomegalovirus</p>
###xml 233 248 233 248 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="90">cytomegalovirus</p></def>
###xml 230 248 230 248 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>CMV</term><def><p textid="90">cytomegalovirus</p></def></def-item>
###xml 248 254 248 254 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NCBInr</term>
###xml 254 313 254 313 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="91">National Center for Biotechnology Information non-redundant</p>
###xml 254 313 254 313 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="91">National Center for Biotechnology Information non-redundant</p></def>
###xml 248 313 248 313 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>NCBInr</term><def><p textid="91">National Center for Biotechnology Information non-redundant</p></def></def-item>
###xml 313 316 313 316 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RPE</term>
###xml 316 342 316 342 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="92">retinal pigment epithelial</p>
###xml 316 342 316 342 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="92">retinal pigment epithelial</p></def>
###xml 313 342 313 342 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>RPE</term><def><p textid="92">retinal pigment epithelial</p></def></def-item>
###xml 342 348 342 348 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N-WASP</term>
###xml 348 389 348 389 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="93">neuronal Wiskott-Aldrich syndrome protein</p>
###xml 348 389 348 389 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="93">neuronal Wiskott-Aldrich syndrome protein</p></def>
###xml 342 389 342 389 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>N-WASP</term><def><p textid="93">neuronal Wiskott-Aldrich syndrome protein</p></def></def-item>
###xml 389 391 389 391 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3D</term>
###xml 391 408 391 408 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="94">three-dimensional</p>
###xml 391 408 391 408 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="94">three-dimensional</p></def>
###xml 389 408 389 408 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>3D</term><def><p textid="94">three-dimensional</p></def></def-item>
###xml 408 415 408 415 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTR-1-P</term>
###xml 415 443 415 443 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="95">methylthioribose 1-phosphate</p>
###xml 415 443 415 443 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="95">methylthioribose 1-phosphate</p></def>
###xml 408 443 408 443 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>MTR-1-P</term><def><p textid="95">methylthioribose 1-phosphate</p></def></def-item>
###xml 443 451 443 451 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTRu-1-P</term>
###xml 451 481 451 481 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="96">methylthioribulose 1-phosphate</p>
###xml 451 481 451 481 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="96">methylthioribulose 1-phosphate</p></def>
###xml 443 481 443 481 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>MTRu-1-P</term><def><p textid="96">methylthioribulose 1-phosphate</p></def></def-item>
###xml 481 484 481 484 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RBD</term>
###xml 484 514 484 514 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="97">Rho binding domain of rhotekin</p>
###xml 484 514 484 514 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="97">Rho binding domain of rhotekin</p></def>
###xml 481 514 481 514 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>RBD</term><def><p textid="97">Rho binding domain of rhotekin</p></def></def-item>
###xml 514 516 514 516 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DN</term>
###xml 516 533 516 533 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="98">dominant negative</p>
###xml 516 533 516 533 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="98">dominant negative</p></def>
###xml 514 533 514 533 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>DN</term><def><p textid="98">dominant negative</p></def></def-item>
###xml 533 535 533 535 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</term>
###xml 535 544 535 544 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="99">wild type</p>
###xml 535 544 535 544 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="99">wild type</p></def>
###xml 533 544 533 544 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>WT</term><def><p textid="99">wild type</p></def></def-item>
###xml 551 553 551 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sub>
###xml 544 553 544 553 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CM-DiIC<sub>18</sub></term>
###xml 553 633 553 633 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="100">chloromethyl-1,1&#8242;-dioctadecyl-3,3,3&#8242;,3&#8242;-tetramethylindocarbocyanine perchlorate.</p>
###xml 553 633 553 633 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="100">chloromethyl-1,1&#8242;-dioctadecyl-3,3,3&#8242;,3&#8242;-tetramethylindocarbocyanine perchlorate.</p></def>
###xml 544 633 544 633 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>CM-DiIC<sub>18</sub></term><def><p textid="100">chloromethyl-1,1&#8242;-dioctadecyl-3,3,3&#8242;,3&#8242;-tetramethylindocarbocyanine perchlorate.</p></def></def-item>
###xml 0 633 0 633 <def-list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><def-item><term>FAK</term><def><p textid="81">focal adhesion kinase</p></def></def-item><def-item><term>MRDI</term><def><p textid="82">mediator of RhoA-dependent invasion</p></def></def-item><def-item><term>RPMI</term><def><p textid="83">RPMI 1640 medium</p></def></def-item><def-item><term>FBS</term><def><p textid="84">fetal bovine serum</p></def></def-item><def-item><term>2DE</term><def><p textid="85">two-dimensional electrophoresis</p></def></def-item><def-item><term>MTA</term><def><p textid="86">methylthioadenosine</p></def></def-item><def-item><term><italic>S</italic>-AdoMet</term><def><p textid="87"><italic>S</italic>-adenosylmethionine</p></def></def-item><def-item><term>RNAi</term><def><p textid="88">RNA interference</p></def></def-item><def-item><term>shRNA</term><def><p textid="89">short hairpin RNA</p></def></def-item><def-item><term>CMV</term><def><p textid="90">cytomegalovirus</p></def></def-item><def-item><term>NCBInr</term><def><p textid="91">National Center for Biotechnology Information non-redundant</p></def></def-item><def-item><term>RPE</term><def><p textid="92">retinal pigment epithelial</p></def></def-item><def-item><term>N-WASP</term><def><p textid="93">neuronal Wiskott-Aldrich syndrome protein</p></def></def-item><def-item><term>3D</term><def><p textid="94">three-dimensional</p></def></def-item><def-item><term>MTR-1-P</term><def><p textid="95">methylthioribose 1-phosphate</p></def></def-item><def-item><term>MTRu-1-P</term><def><p textid="96">methylthioribulose 1-phosphate</p></def></def-item><def-item><term>RBD</term><def><p textid="97">Rho binding domain of rhotekin</p></def></def-item><def-item><term>DN</term><def><p textid="98">dominant negative</p></def></def-item><def-item><term>WT</term><def><p textid="99">wild type</p></def></def-item><def-item><term>CM-DiIC<sub>18</sub></term><def><p textid="100">chloromethyl-1,1&#8242;-dioctadecyl-3,3,3&#8242;,3&#8242;-tetramethylindocarbocyanine perchlorate.</p></def></def-item></def-list>
###xml 92 98 <span type="species:ncbi:9913">bovine</span>
FAKfocal adhesion kinaseMRDImediator of RhoA-dependent invasionRPMIRPMI 1640 mediumFBSfetal bovine serum2DEtwo-dimensional electrophoresisMTAmethylthioadenosineS-AdoMetS-adenosylmethionineRNAiRNA interferenceshRNAshort hairpin RNACMVcytomegalovirusNCBInrNational Center for Biotechnology Information non-redundantRPEretinal pigment epithelialN-WASPneuronal Wiskott-Aldrich syndrome protein3Dthree-dimensionalMTR-1-Pmethylthioribose 1-phosphateMTRu-1-Pmethylthioribulose 1-phosphateRBDRho binding domain of rhotekinDNdominant negativeWTwild typeCM-DiIC18chloromethyl-1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate.
###end p 80
###begin p 81
focal adhesion kinase
###end p 81
###begin p 82
mediator of RhoA-dependent invasion
###end p 82
###begin p 83
RPMI 1640 medium
###end p 83
###begin p 84
###xml 6 12 <span type="species:ncbi:9913">bovine</span>
fetal bovine serum
###end p 84
###begin p 85
two-dimensional electrophoresis
###end p 85
###begin p 86
methylthioadenosine
###end p 86
###begin p 87
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
S-adenosylmethionine
###end p 87
###begin p 88
RNA interference
###end p 88
###begin p 89
short hairpin RNA
###end p 89
###begin p 90
cytomegalovirus
###end p 90
###begin p 91
National Center for Biotechnology Information non-redundant
###end p 91
###begin p 92
retinal pigment epithelial
###end p 92
###begin p 93
neuronal Wiskott-Aldrich syndrome protein
###end p 93
###begin p 94
three-dimensional
###end p 94
###begin p 95
methylthioribose 1-phosphate
###end p 95
###begin p 96
methylthioribulose 1-phosphate
###end p 96
###begin p 97
Rho binding domain of rhotekin
###end p 97
###begin p 98
dominant negative
###end p 98
###begin p 99
wild type
###end p 99
###begin p 100
chloromethyl-1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate.
###end p 100
###begin title 101
REFERENCES
###end title 101
###begin article-title 102
Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma.
###end article-title 102
###begin article-title 103
###xml 21 26 <span type="species:ncbi:9606">human</span>
Molecular biology of human melanoma development and progression.
###end article-title 103
###begin article-title 104
Rho GTPases: biochemistry and biology.
###end article-title 104
###begin article-title 105
Genomic analysis of metastasis reveals an essential role for RhoC.
###end article-title 105
###begin article-title 106
###xml 69 73 <span type="species:ncbi:10090">mice</span>
A definitive role of RhoC in metastasis of orthotopic lung cancer in mice.
###end article-title 106
###begin article-title 107
Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma.
###end article-title 107
###begin article-title 108
Role of Rho-family proteins in cell adhesion and cancer.
###end article-title 108
###begin article-title 109
Rho-GTPases and cancer.
###end article-title 109
###begin article-title 110
Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase).
###end article-title 110
###begin article-title 111
Cooperation between mDia1 and ROCK in Rho-induced actin reorganization.
###end article-title 111
###begin article-title 112
mDia mediates Rho-regulated formation and orientation of stable microtubules.
###end article-title 112
###begin article-title 113
Rac activation and inactivation control plasticity of tumor cell movement.
###end article-title 113
###begin article-title 114
Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.
###end article-title 114
###begin article-title 115
FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly.
###end article-title 115
###begin article-title 116
Molecular complexity and dynamics of cell-matrix adhesions.
###end article-title 116
###begin article-title 117
The interplay between Src and integrins in normal and tumor biology.
###end article-title 117
###begin article-title 118
Adhesion assembly, disassembly, and turnover in migrating cells.
###end article-title 118
###begin article-title 119
Melanoma: the Wistar melanoma (WM) cell lines.
###end article-title 119
###begin article-title 120
###xml 25 30 <span type="species:ncbi:9606">human</span>
Biological properties of human melanoma cells in culture.
###end article-title 120
###begin article-title 121
###xml 24 29 <span type="species:ncbi:9606">human</span>
In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.
###end article-title 121
###begin article-title 122
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells.
###end article-title 122
###begin article-title 123
Melanoma cell lines from different stages of progression and their biological and molecular analyses.
###end article-title 123
###begin article-title 124
Efficient selection of recombinant adenoviruses by vectors that express beta-galactosidase.
###end article-title 124
###begin article-title 125
###xml 50 55 <span type="species:ncbi:9606">human</span>
Picomolar transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase and x-ray structure with MT-immucillin-A.
###end article-title 125
###begin article-title 126
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.
###end article-title 126
###begin article-title 127
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.
###end article-title 127
###begin article-title 128
Two-dimensional gel electrophoresis for the identification of signaling targets.
###end article-title 128
###begin article-title 129
Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels.
###end article-title 129
###begin article-title 130
Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels.
###end article-title 130
###begin article-title 131
Image processing with ImageJ.
###end article-title 131
###begin article-title 132
###xml 77 98 77 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Klebsiella pneumoniae</italic>
###xml 77 98 <span type="species:ncbi:573">Klebsiella pneumoniae</span>
Intermediates in the conversion of 5'-S-methylthioadenosine to methionine in Klebsiella pneumoniae.
###end article-title 132
###begin article-title 133
Determination of GTP loading on Rho.
###end article-title 133
###begin article-title 134
Cytoskeletal organization in tropomyosin-mediated reversion of ras-transformation: Evidence for Rho kinase pathway.
###end article-title 134
###begin article-title 135
Regulating actin dynamics in neuronal growth cones by ADF/cofilin and rho family GTPases.
###end article-title 135
###begin article-title 136
Regulation of microtubule destabilizing activity of Op12/stathmin downstream of Rac1.
###end article-title 136
###begin article-title 137
Functional proteomics identifies protein tyrosine phosphatase 1B as a target of RhoA signaling.
###end article-title 137
###begin article-title 138
###xml 14 19 <span type="species:ncbi:9606">human</span>
RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway.
###end article-title 138
###begin article-title 139
Regulation of actin dynamics by WASP family proteins.
###end article-title 139
###begin article-title 140
Archaeal translation initiation revisited: the initiation factor 2 and eukaryotic initiation factor 2B alpha-beta-delta subunit families.
###end article-title 140
###begin article-title 141
Bacterial variations on the methionine salvage pathway.
###end article-title 141
###begin article-title 142
Methionine synthesis from 5'-S-Methylthioadenosine. Resolution of enzyme activities and identification of 1-phospho-5-S methylthioribulose.
###end article-title 142
###begin article-title 143
A functional link between RuBisCO-like protein of Bacillus and photosynthetic RuBisCO.
###end article-title 143
###begin article-title 144
###xml 21 26 <span type="species:ncbi:4932">yeast</span>
Crystal structure of yeast Ypr118w, a methylthioribose-1-phosphate isomerase related to regulatory eIF2B subunits.
###end article-title 144
###begin article-title 145
###xml 83 100 83 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus subtilis</italic>
###xml 83 100 <span type="species:ncbi:1423">Bacillus subtilis</span>
Crystal structure of 5-methylthioribose 1-phosphate isomerase product complex from Bacillus subtilis: implications for catalytic mechanism.
###end article-title 145
###begin article-title 146
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.
###end article-title 146
###begin article-title 147
Bifunctional and moonlighting enzymes: lighting the way to regulatory control.
###end article-title 147
###begin article-title 148
5'-Deoxy-5'-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines.
###end article-title 148
###begin article-title 149
###xml 151 156 <span type="species:ncbi:9606">human</span>
Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), 1996. methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy.
###end article-title 149
###begin article-title 150
Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
###end article-title 150
###begin article-title 151
A transition state analogue of 5'-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers.
###end article-title 151
###begin article-title 152
Direct and tumor microenvironment mediated influences of 5'-deoxy-5'-(methylthio)adenosine on tumor progression of malignant melanoma.
###end article-title 152

